Every 424B that Sagimet Biosciences Inc. Series A (SGMT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SGMT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGMT filings page.
Sagimet Biosciences Inc. (SGMT) is offering 8,750,010 shares of Series A common stock and pre-funded warrants to purchase 2,750,010 shares. Prices are $10.00 per share and $9.9999 per warrant; warrants are immediately exercisable at $0.0001 per share. The aggregate offering price is $114,999,925; estimated net proceeds are approximately $107.5 million, excluding proceeds from warrant exercises. Sagimet intends to use proceeds and existing cash for denifanstat’s planned Phase 3 acne trial and pre-launch work, TVB-3567 through Phase 2 topline results, its topical FASN inhibitor program through IND submission, and general corporate purposes. Immediate dilution to new investors is calculated at $4.87 per share.
Sagimet reported 52-week results from a China open-label extension involving 240 acne patients: overall treatment success was 56.7%, and mean total lesion count change from baseline was -71.8%. It plans a U.S. registrational Phase 3 acne trial in the second half of 2026; a TVB-3567 Phase 2 trial is anticipated before year-end 2026, subject to regulatory consultation and Phase 1 results.
The pre-funded warrants have no established public trading market. Sagimet says it will undertake no further MASH clinical development until it obtains non-dilutive financing.
Sagimet Biosciences Inc. suspended its at-the-market sales through Leerink Partners LLC and terminated the continuous offering under its prospectus supplement, effective September 30, 2026. The company had sold no shares under the Sales Agreement as of September 30, 2026. It will not make further sales unless and until a new prospectus supplement is filed; the Sales Agreement remains in full force and effect.
Sagimet Biosciences is offering 29,166,700 shares of Series A common stock at $6.00 per share, for an aggregate offering price of $175,000,200 via a shelf prospectus supplement. The underwriters’ discount is $0.36 per share, providing estimated net proceeds to the company of approximately $163.9 million. The shares are expected to be delivered on or about April 28, 2026. Proceeds are intended to fund a Phase 3 acne trial for denifanstat, advance TVB-3567 through Phase 2 topline results, support a topical FASN program to IND, and for general corporate purposes. The supplement discloses a preliminary cash balance of approximately $104.5 million as of March 31, 2026 (unaudited).